NCT04520230View on ClinicalTrials.gov

Three Treatment of Chronic Obstructive Pulmonary Disease Patients

PHASE4CompletedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

October 31, 2014

Primary Completion Date

December 30, 2019

Study Completion Date

December 31, 2019

Conditions
COPD
Interventions
DRUG

Budesonide/Formoterol combination 160/4.5 mcg, 2 inhalations bid

inhaled corticosteroid (ICS)plus long acting B2-agonist (LABA) (Budesonide/Formoterol combination 160/4.5 mcg, 2 inhalations bid ).

DRUG

Tiotropium 18 mcg capsule inhaled once daily + Budesonide

inhaled corticosteroid (ICS) plus long acting anticholinergic (LAAC) (Tiotropium 18 mcg capsule inhaled once daily + Budesonide ).

DRUG

Formoterol/Tiotropium

long acting B2-agonist (LABA) plus long acting anticholinergic (LAAC).

All Listed Sponsors
lead

Tanta University

OTHER

NCT04520230 - Three Treatment of Chronic Obstructive Pulmonary Disease Patients | Biotech Hunter | Biotech Hunter